Filing Flows › BioCorRx (BICX) › Q1 2026
BioCorRx (BICX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
BioCorRx (BICX) reported revenue of $215K for the first quarter 2026 (Q1 2026), +59% from a year earlier. Operating margin was -445.6%, net loss $860K (400.8% of revenue).
BioCorRx, Q1 2026: revenue $215K (+59% year over year), operating margin -445.6%, net loss $860K, operating cash flow −$433K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $215K | — | +59% |
| Operating profit | −$956K | — | — |
| Net earnings | −$860K | — | — |
| Operating cash flow | −$433K | — | — |
What changed
Revenue was $215K in Q1 2026, up 59% year over year.
Operating costs exceeded revenue by $1.0M, an operating margin of -445.6%. Total costs grew 9% against revenue growth of 59%. The fastest-growing cost line was Research & development (+118%). The quarter ended with a net loss of $860K. Minority interests bore $29K of it: to shareholders the quarter was a loss of $831K.
Operating cash flow was −$433K. Non-cash charges added back $11K of depreciation and amortization and $108K of share-based compensation. Working capital and other items added $307K.
Questions
What was BioCorRx's revenue in the first quarter 2026?
BioCorRx (BICX) reported revenue of $215K for the first quarter 2026 (Q1 2026), +59% from a year earlier.
Was BioCorRx profitable in the first quarter 2026?
Operating loss was $956K (-445.6% of revenue) and net loss $860K.
Source: BioCorRx 10-Q on SEC EDGAR.